Arexvy

News

GSK's RSV shot cleared in US for all adults

GSK is back on level pegging with its rivals in the RSV vaccine category in the US, after getting FDA approval for Arexvy in the 18 to 49 age bracket.

News

CHMP decision levels the playing field for GSK's RSV jab

GSK's RSV vaccine is poised for EU approval in all adults aged 18 and over, bringing it into line with rival shots from Pfizer and Moderna.

News

Could a vaccine adjuvant be protective against dementia?

Scientists behind a study suggesting GSK's RSV vaccine may be protective against dementia have said the adjuvant used in it may be responsible.

News

Stéphane Bancel, Moderna's chief executive

Moderna's RSV shot gets US nod for use in younger adults

The label for Moderna's RSV vaccine mResvia has been expanded to include adults aged 18 and over in the US, but will that lead to an uptick in sales?

News

There's good news for RSV jab firms at delayed ACIP meeting

GSK and Pfizer could see a resurgence in sales of their RSV vaccines if new recommendations at a CDC expert meeting are confirmed by agency leaders.

News

GSK rides out vaccine sales weakness with cancer, HIV gains

Despite a steep fall-off in sales of RSV vaccine Arexvy last year, GSK has raised its long-term sales forecast to £40 billion in 2031.

GSK's RSV shot cleared in US for all adults

CHMP decision levels the playing field for GSK's RSV jab

Could a vaccine adjuvant be protective against dementia?

Moderna's RSV shot gets US nod for use in younger adults

There's good news for RSV jab firms at delayed ACIP meeting

GSK rides out vaccine sales weakness with cancer, HIV gains

AbbVie tries a new approach in 340B programme battle

Using AI-driven synthetic personas to take your insights fur...

Arexvy

Editor's Picks